Genprex Inc. has released its latest financial results, highlighting a significant variation in its performance metrics. The company reported a notable change in its financial status compared to the previous period, with a focus on its clinical development, manufacturing, and commercialization efforts. Although specific figures for sales, revenues, and net income/profit/loss were not detailed, the company emphasized its ongoing commitment to advancing its product candidates for cancer and diabetes treatments. Additionally, Genprex provided an outlook on its future growth and financial status, underscoring its ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market. The company remains focused on obtaining the necessary capital to meet its long-term liquidity needs and expanding its strategic partnerships, including those with third-party vendors and manufacturers.